Peptide Schedule
Setmelanotide8 residues (approx.)CEHFRWCKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Setmelanotide Dosage Calculator
Setmelanotide is the first and only FDA-approved treatment targeting the melanocortin-4 receptor (MC4R) pathway for patients with rare genetic obesity disorders.
1mg · Daily
Summary: Add 2mL BAC water to your 10mg vial. Draw to 20.0 units on a U-100 syringe for a 1mg dose. This vial will last 10 doses.
Cycle Planner
Setmelanotide Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~11 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Setmelanotide Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mg | Daily |
| Moderate | 2mg | Daily |
| Aggressive | 3mg | Daily |
Note: FDA-approved as IMCIVREE for genetic obesity only (POMC, PCSK1, LEPR, BBS deficiency). Requires confirmed genetic testing before prescribing. Titrate from 1mg daily. Monitor for skin hyperpigmentation.
About Setmelanotide
Setmelanotide is the first and only FDA-approved treatment targeting the melanocortin-4 receptor (MC4R) pathway for patients with rare genetic obesity disorders. Sold under the brand name IMCIVREE, it was approved in November 2020 for adults and children aged 6+ with obesity caused by POMC, PCSK1, or LEPR deficiency confirmed by genetic testing — and later expanded to include Bardet-Biedl syndrome in 2022. Unlike GLP-1 agonists that work through gut hormones and appetite signaling, setmelanotide acts directly on MC4R in the hypothalamus to restore the satiety signaling that these patients are missing due to their genetic mutations. In patients with POMC deficiency, the body cannot produce alpha-MSH, the natural ligand for MC4R. Setmelanotide steps in as a synthetic replacement, reactivating the downstream hunger-off switch. The clinical results in the right patient population are striking. In phase 3 trials, 80% of POMC-deficient patients achieved at least 10% body weight loss at one year, with a mean reduction of 25.6%. LEPR-deficient patients saw a mean 12.5% weight loss. These are patients who previously had zero effective treatment options and experienced constant, unrelenting hunger from birth. Setmelanotide is an 8-amino-acid cyclic peptide — structurally related to alpha-MSH but engineered for selectivity at MC4R over MC1R, though it still activates MC1R enough to cause skin darkening (hyperpigmentation) in most patients. It comes as a 10mg/mL multi-dose vial for daily subcutaneous injection. The 11-hour half-life means steady-state is reached within about 2 days of daily dosing.